Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.
Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.
The profit decline resulted from no longer consolidating the results of JBM Healthcare, a Thursday filing with the Hong Kong Exchange said.
The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.
The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.
The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。